M
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Manit Munshi's research focuses on Waldenström macroglobulinemia, a rare B-cell lymphoma. His work has investigated various therapeutic agents and their efficacy in treating this condition, including ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, and the CXCR4 antagonist ulocuplumab. Munshi has also examined mechanisms of resistance to these therapies and explored novel drug combinations, such as ibrutinib with venetoclax. A significant area of his research involves the diagnostic challenges in detecting key mutations like MYD88L265P and CXCR4 in Waldenström macroglobulinemia, particularly concerning next-generation sequencing methods. His publications include studies on treatment-naive patients, long-term follow-up data, and predictors of response and survival in patients treated with ibrutinib monotherapy. Munshi also investigates the activity of new kinase inhibitors, such as KIN-8194, in MYD88-driven lymphomas, aiming to overcome existing resistance pathways. His research network includes collaborators such as Guido Tricot, David E. Mery, and Maurizio Zangari, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 20
- Publications: 70
- Citations: 1,490
Selected Publications
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
-
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS (2023)
Collaboration Network
Top Collaborators
Amanda Kofides
Dana-Farber Cancer Institute (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Maria Luisa Guerrera
Dana-Farber Cancer Institute (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Kirsten Meid
Dana-Farber Cancer Institute (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Zachary R. Hunter
Dana-Farber Cancer Institute (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Jorge J. Castillo
Dana-Farber Cancer Institute (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Steven P. Treon
Harvard University (US)
16 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 16 shared publications
Christopher J. Patterson
Dana-Farber Cancer Institute (US)
15 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 15 shared publications
Shayna Sarosiek
Dana-Farber Cancer Institute (US)
15 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
- Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
Showing 5 of 15 shared publications
Catherine Flynn
Dana-Farber Cancer Institute (US)
14 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
- Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
Showing 5 of 14 shared publications
Joshua Gustine
Boston Medical Center (US)
13 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
- Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
- Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
Showing 5 of 13 shared publications
Andrew R. Branagan
Harvard University (US)
13 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
- Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
Showing 5 of 13 shared publications
Guang Yang
Dana-Farber Cancer Institute (US)
11 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 11 shared publications
Nicholas Tsakmaklis
Dana-Farber Cancer Institute (US)
9 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 9 shared publications
Maria Demos
Dana-Farber Cancer Institute (US)
9 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 9 shared publications
Lian Xu
Dana-Farber Cancer Institute (US)
8 shared publications
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
- The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
- Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Sydnye L. Shuttleworth
University of Arkansas for Medical Sciences
Lymphoma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Zhixing Wang
University of Arkansas for Medical Sciences
Drug Transport and Resistance Mechanisms
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
R. Eric Davis
University of Arkansas for Medical Sciences
Drug Transport and Resistance Mechanisms
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Jamie Ferguson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer Genomics and Diagnostics
Cancer-related molecular mechanisms research
Ying-Zhi Xu
University of Arkansas for Medical Sciences
Lymphoma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Hong-yu Li
University of Arkansas for Medical Sciences
Drug Transport and Resistance Mechanisms
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research